KEY FACTS Two late-breaking presentations from the landmark OCEANIC-STROKE study will provide new insights into ischemic strokes that occurred during the trial, as well...
The Latest Breakthrough Study from Leaps by Bayer and BCG reveals why optimism varies by technology, region, and context, with varying trends in China, Germany, and the US Younger generations...
Bayer Canada is proud to support the Simon Fraser University (SFU) School of Medicine - the first medical school in Western Canada in nearly 60 years. The new school is dedicated to help improve primary...
Nelson Ambrogio appointed to lead U.S. pharmaceuticals business, Bayer’s largest pharmaceutical growth market Appointment supports Bayer Pharmaceuticals’ strategy to renew top-line...
Bayer challenges industry to redefine canola innovation and reframe canola's future around real, lasting systems.
The social-first campaign humorously tackles extreme wellness trends while showcasing how Ludacris incorporates One A Day ® multivitamins...
Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary...
KERENDIA ® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline...
Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions Expanded Tesla compatibility captures...
 225 Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC)...